Synairgen (SNG) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Sep 2022 07:00 AM
RNS
Positive Findings from SG015 Tri-al Analysis
05 Sep 2022 07:00 AM
RNS
Company Announce Collaboration on UNIVERSAL Trial
06 Jul 2022 07:00 AM
RNS
Grant of Options
30 Jun 2022 01:45 PM
RNS
Result of AGM
23 Jun 2022 04:40 PM
RNS
Second Price Monitoring Extn
23 Jun 2022 04:35 PM
RNS
Price Monitoring Extension
15 Jun 2022 02:30 PM
RNS
Holding(s) in Company
09 Jun 2022 03:00 PM
RNS
Exercise of Options and Total Voting Rights
06 Jun 2022 04:25 PM
RNS
Posting of Annual Report & Notice of AGM
25 May 2022 07:00 AM
RNS
Full Year Results
18 May 2022 04:36 PM
RNS
Price Monitoring Extension
16 May 2022 07:00 AM
RNS
Synairgen presents at ATS 2022
25 Apr 2022 07:00 AM
RNS
Presentation at ECCMID
19 Apr 2022 04:40 PM
RNS
Second Price Monitoring Extn
19 Apr 2022 04:35 PM
RNS
Price Monitoring Extension
06 Apr 2022 02:10 PM
RNS
Holding(s) in Company
05 Apr 2022 07:00 AM
RNS
Synairgen to present at ATS 2022
17 Mar 2022 07:25 AM
RNS
Synairgen Provides Update on ACTIV-2 Trial
14 Mar 2022 04:41 PM
RNS
Second Price Monitoring Extn
14 Mar 2022 04:36 PM
RNS
Price Monitoring Extension
11 Mar 2022 04:40 PM
RNS
Second Price Monitoring Extn
11 Mar 2022 04:35 PM
RNS
Price Monitoring Extension
08 Mar 2022 04:35 PM
RNS
Holding(s) in Company
08 Mar 2022 03:52 PM
RNS
Holding(s) in Company
04 Mar 2022 01:36 PM
RNS
Holding(s) in Company
03 Mar 2022 07:00 AM
RNS
Update on SNG001
24 Feb 2022 11:30 AM
RNS
Holding(s) in Company
23 Feb 2022 11:25 AM
RNS
Holding(s) in Company
21 Feb 2022 07:00 AM
RNS
Topline results from Phase 3 SPRINTER trial
04 Feb 2022 04:54 PM
RNS
Holding(s) in Company
28 Jan 2022 07:00 AM
RNS
Director/PDMR Shareholding
19 Jan 2022 02:05 PM
RNS
Holding(s) in Company
12 Jan 2022 11:53 AM
RNS
Holding(s) in Company
07 Jan 2022 05:25 PM
RNS
Holding(s) in Company
06 Jan 2022 12:00 PM
RNS
Synairgen announces partnership with Ashfield
23 Dec 2021 04:15 PM
RNS
Holding(s) in Company
23 Dec 2021 02:19 PM
RNS
Holding(s) in Company
21 Dec 2021 05:05 PM
RNS
Holding(s) in Company
08 Dec 2021 07:00 AM
RNS
Data Presented at ESWI Influenza Conference
06 Dec 2021 05:30 PM
RNS
Holding(s) in Company
06 Dec 2021 07:00 AM
RNS
Synairgen Presents SNG001 Data at ESWI
19 Nov 2021 02:26 PM
RNS
Holding(s) in Company
11 Nov 2021 07:00 AM
RNS
Synairgen completes Phase III recruitment
08 Nov 2021 12:58 PM
RNS
Holding(s) in Company
26 Oct 2021 03:13 PM
RNS
Holding(s) in Company
21 Oct 2021 05:39 PM
RNS
Holdings in Company
21 Oct 2021 07:00 AM
RNS
Grant of Options
20 Oct 2021 07:00 AM
RNS
SNG001 progresses to Phase 3 of ACTIV-2 trial
13 Oct 2021 07:00 AM
RNS
Synairgen appoints Gareth Walters, Ph.D. as CRO
05 Oct 2021 11:25 AM
RNS
Holding(s) in Company

Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic.

Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections.

Synairgen share price launched at 155p in 2004.

UK 100

Latest directors dealings